Understanding pathogen and host determinants of the natural history of N. gonorrhoeae infection
- Institution
- UNIV OF NORTH CAROLINA CHAPEL HILL, NC
- Principal investigator
- Joseph A Duncan
- Funding
- $665K
- Duration
- 2023–2028
Moonbase score
Still being scored
Abstract
Abstract: Rising antibiotic resistance in N. gonorrhoeae poses a serious, global public health threat. Effective control of N. gonorrhoeae is hampered by asymptomatic infections that allow transmission of the bacteria to uninfected individuals and immune evasion by the bacteria that has limited vaccine development efforts. Understanding the natural history of asymptomatic infection and the immunologic responses that are responsible for clearance of infection. We propose a longitudinal study with close surveillance and of follow up individuals with recent N. gonorrhoeae infection who are at high risk for re-infection. This study will provide a rich data set to understand pathogen exposure and infection outcome. It will also provide a set of biologic specimens to study the pathogen and host factors that contribute to infection clearance as well as asymptomatic carriage and/or progression to symptomatic infection. We will conduct analysis of anti-N. gonorrhoeae antibody and cellular immune responses to inform correlates of protective immunity against gonorrhea. Combined this project will provide important new information that will contribute to public health and vaccine development efforts to reduce the spread of N. gonorrhoeae.
LOADING MOONBASE SCORE
Questions for UNIV OF NORTH CAROLINA CHAPEL HILL
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Univ of North Carolina Chapel HillNot yet scored
Efficacy of immunization with 4C-MenB in preventing experimental urethral infection with Neisseria gonorrhoeae.
Joseph A Duncan · $777K · 2021–2026
- NIH · Univ of North Carolina Chapel Hill65
Cortical circuits for the integration of parallel short-latency auditory pathways
Hiroyuki Kato · $469K · 2022–2027
- NIH · Univ of North Carolina Chapel Hill47
Study to establish safety, tolerability and feasibility of LM11A-31 as a neuroprotective agent in aging people living with HIV and neurocognitive impairment on antiretroviral therapy
Rick B Meeker · $638K · 2023–2029